Drug Profile


Alternative Names: MK-3814; Privadenant; SCH 420814

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough
  • Class Antiparkinsonians; Bridged-ring heterocyclic compounds; Piperazines; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 27 Jun 2017 Phase-I/II clinical trials in Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater) in Israel (PO) (NCT03099161)
  • 21 Apr 2017 Merck terminates a phase II trial in Drug-induced akathisia in South Africa (PO) (NCT00693472)
  • 07 Apr 2017 Merck plans the MK-3814A-062 phase I trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease) in USA, Canada and Israel (NCT03099161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top